Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SACRED: APG-2575 Alone or in Combination in Relapsed/Refractory CLL/SLL
2024-515654-25-00Phase 2Authorised
- Sponsor
- Ascentage Pharma
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of lisaftoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (5 arms), sponsored by Ascentage Pharma. Primary endpoints: Safety and tolerability, Maximum tolerated dose (MTD) and 1 more. Planned start Dec 2021; status: authorised.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-515654-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515654-25-00.